NCT04522986View on ClinicalTrials.gov

An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 21, 2020

Primary Completion Date

February 2, 2021

Study Completion Date

February 2, 2021

Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
BIOLOGICAL

Mesenchymal stem cell

1\*10\^8 cells are administered once a week, total four times intravenously.

Trial Locations (1)

565-0871

Osaka University Hospital, Suita

All Listed Sponsors
lead

Rohto Pharmaceutical Co., Ltd.

INDUSTRY

NCT04522986 - An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection | Biotech Hunter | Biotech Hunter